Innate Pharma Lands $75M Upfront in Lacutamab Deal with Sobi
IPHA sits 48% above its 52-week low of $1.17 on light trading volume (0.1× avg).
Summary
Innate Pharma secures a transformative partnership with Sobi for lacutamab, its lead asset in cutaneous T-cell lymphoma. Sobi pays $75 million upfront, with up to $40 million in near-term milestones and a total potential of $465 million plus tiered double-digit royalties. The deal funds the pivotal TELLOMAK-3 Phase 3 trial, a critical step toward accelerated approval in Sézary syndrome. This follows Innate's May disclosure of a cash runway only into Q3 2026 — the upfront payment directly addresses that liquidity crunch. Sobi gains exclusive global commercialization rights upon accelerated approval, with an option for full development rights after Phase 3. The partnership validates lacutamab's potential and provides non-dilutive capital at a crucial juncture.
Updates
· SEC 6-K — The 6-K includes a second press release announcing Markus Jensen as Chief Medical Officer effective September 1, 2026, succeeding Sonia Quaratino. The upfront payment is expected to extend cash runway through Q3 2027.
At the time of this announcement, IPHA was trading at $1.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.6M. The 52-week trading range was $1.17 to $2.62. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.